2013
-
Short and long-term cost-effectiveness of switching therapy from NPH insulin to insulin detemir in people with type 2 diabetes. PD Home et al.Key findings: Switching from NPH±OGLDs to detemir±OGLDs in people with T2DM as performed in the A1chieve® study was found to be cost-effective in both country settings at 1 and 30 year time horizons.
-
Short and long-term cost-effectiveness of switching therapy from insulin glargine to insulin detemir in people with type 2 diabetes R Malek et al.Key findings: Switching therapy from insulin glargine to insulin detemir in T2DM as performed in the A1chieve® study was found to be highly cost-effective across all country settings based on a 1 and 30-year time horizon. Sensitivity analyses showed the long-term costeffectiveness to be robust. Predicted life-expectancy increased and the relative risk of complications was reduced across all country settings based on a 30-year time horizon.
-
Short and long-term cost-effectiveness of initiating biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes. PD Home et al.Key findings: Initiating biphasic insulin aspart 30 in insulin-naive people in Saudi Arabia, India, Indonesia and Malaysia was found to be cost effective over both a 1-year and a 30-year time horizon.
-
Short and long-term cost-effectiveness of switching therapy from biphasic human insulin 30 to biphasic insulin aspart 30 in people with type 2 diabetes. PD Home et al.Key findings: Switching from biphasic human insulin 30 ± OAD s to biphasic insulin aspart 30 ± OAD s was found to be cost-effective in India, Malaysia and Saudi Arabia at 1- and 30-year time horizons.
-
Short and long-term cost-effectiveness of switching therapy from insulin glargine to biphasic insulin aspart 30 in people with type 2 diabetes in Saudi Arabia and India. PD Home et al.Key findings: The switch from insulin glargine to biphasic insulin aspart 30 in Saudi Arabia and India was found to be less costly and have better outcomes over both a 1-year and a 30-year time horizon.
-
Short and long-term cost-effectiveness of initiating insulin detemir in insulin-naïve people with type 2 diabetes. PD Home et al.Key findings: Initiating insulin detemir in insulin-naïve people in Algeria, India, Indonesia, Malaysia, Mexico and South Korea was found to be cost effective over both a 1-year and a 30-year time horizon.
